Phenoxybenzamine

Phenoxybenzamine

Clinical data
Pregnancy category	C (U.S.)
Routes of administration	Oral
ATC code	C04AX02 (WHO)
Pharmacokinetic data
Elimination half-life	24 hours
Identifiers
IUPAC name N-benzyl-N-(2-chloroethyl)-1-phenoxy-propan-2-amine
CAS Number	59-96-1
PubChem CID	4768
DrugBank	APRD00651
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H22ClNO
Molar mass	303.826 g/mol

Phenoxybenzamine (marketed under the trade name Dibenzyline) is a non-specific, irreversible alpha blocker used in the treatment of hypertension, and specifically that caused by pheochromocytoma. It has a slower onset and a longer lasting effect compared with other alpha blockers. It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia, although it is currently seldom used for that indication due to an unfavourable side effects profile.

Pharmacology

Phenoxybenzamine is used as an anti-hypertensive due to its efficacy in reducing the vasoconstriction caused by adrenaline and noradrenaline. Phenoxybenzamine forms a permanent covalent bond with adrenergic receptors. Based on what we know about the structures of these receptors, it likely involves attack by the cysteine at position 3.36 in transmembrane helix 3 to form a stable linkage. Thus, it remains permanently bound to the receptor, preventing adrenaline and noradrenaline from binding. This causes vasodilatation in blood vessels, due to its antagonistic effect at the alpha-1 adrenoceptor found in the walls of blood vessels, resulting in a drop in blood pressure.

It will also affect the alpha 1 and 2 receptors found in the nervous system, where this will reduce sympathetic activity. This is due to its effect on the postsynaptic membrane adrenoceptors in the second synapse of the sympathetic nervous pathway, and will therefore reduce the 'fight or flight' output of the sympathetic nervous system. This results in further general vasodilation, pupil constriction, an increase in GI tract motility and secretions, and glycogen synthesis.

It also has partial agonist/antagonist properties at the serotonin 5-HT2A receptor.

References

• Day, M.D. (1979). Autonomic Pharmacology Experimental and Clinical Aspects. Churchill Livingstone.
• Bullock, S. Galbraith, A. Hunt, B. Manias, E. and Richards, A. (1999). Fundamentals of Pharmacology. Pearson Education Limited publishing as Prentice Hall.